The Therapeutic Goods Administration (TGA) Explained

About 350,000 Australians are currently accessing medicinal cannabis through legal channels, according to TGA approval data. That number has roughly doubled in three years. Behind every one of those approvals sits the Therapeutic Goods Administration, and yet the way its framework actually works is often reduced to a confident muddle of half-remembered headlines.

That is understandable. The Poisons Standard (formally, the Standard for the Uniform Scheduling of Medicines and Poisons, or SUSMP) is not light reading. But the structure, once you see it clearly, is logical. So let me try to map it, layer by layer, and flag the places where the public conversation most often goes wrong.

One note before we start. This article describes how regulation works. It is not advice about any product or pathway, and nothing here is a recommendation to use any substance. Questions about a particular person's situation belong with a qualified health professional.

What the Therapeutic Goods Administration actually does

The Therapeutic Goods Administration is a regulatory division of the Australian Department of Health and Aged Care. Its mandate under the Therapeutic Goods Act 1989 (Cth) is to assess and regulate therapeutic goods (medicines, medical devices and biologicals) before they reach Australians. Think of it as a gatekeeper sitting between manufacturers and the public, responsible for evaluating quality, safety and, where evidence exists, efficacy.

The word "where" in that last sentence matters. Quality and safety assessment applies broadly, but efficacy evidence is weighed differently depending on the type of good and the pathway it travels. A reader who assumes every product the TGA touches has been through the same evidentiary test will misread most of the cannabis picture.

The TGA maintains the Australian Register of Therapeutic Goods (ARTG), the database of every product that may lawfully be supplied in Australia. If a product isn't on the ARTG, supplying it is generally an offence. That single fact explains a lot about how cannabis access has been structured: most medicinal cannabis products in Australia are not fully registered on the ARTG in the way, say, aspirin is. They move through a different lane entirely. For a closer look at the register itself, see The ARTG: Registered vs Unregistered Medicines, and for the history behind the agency, How the TGA Came to Be.

How scheduling works: the Poisons Standard

Alongside the ARTG sits the scheduling system. The Poisons Standard divides medicines and controlled substances into schedules based on their risk profile, therapeutic value and potential for misuse. A schedule is essentially a label that determines who may supply a substance and under what conditions, from open retail sale at one end to tightly controlled supply at the other. Two schedules are central to the cannabis conversation, and the glossary entry on the Poisons Standard gives the short definition if you want it.

Schedule 4 (Prescription Only) covers medicines that require a prescription from an authorised practitioner but are considered lower-risk than the next category. Since 2017, low-cannabidiol products meeting certain criteria have been rescheduled progressively, and from February 2021 certain low-dose CBD preparations became available without a prescription under Schedule 3, though the strict formulation criteria mean very few products have actually met that bar in practice.

Schedule 8 (Controlled Drug) is where cannabis products containing tetrahydrocannabinol (THC) above specified thresholds sit. Schedule 8 drugs require a prescription, and in most Australian states and territories they also require an additional permit from the relevant state health authority before a pharmacist can legally dispense them. This two-layer requirement, federal scheduling plus state permit, is one of the genuinely cumbersome parts of the current framework, and I'll admit it surprises even experienced clinicians when they first encounter it.

A common mistake is to treat the schedule number as a ranking of how "strong" a product is. It is not. Scheduling reflects a package of considerations about risk, usefulness and misuse potential, and the two schedules above differ mainly in how supply is controlled. The comparison is laid out in Schedule 4 vs Schedule 8: What They Mean, with more on the document itself in The Poisons Standard (SUSMP) Explained.

The two main access pathways: SAS and Authorised Prescriber

Because the vast majority of medicinal cannabis products are unapproved goods (not fully registered on the ARTG), accessing them legally requires going through one of two pathways that the TGA administers for unapproved medicines. The legal logic behind that arrangement is covered in Unapproved Therapeutic Goods: The Legal Basis.

The first is the Special Access Scheme (SAS). Under SAS Category B, a medical practitioner submits an application to the TGA on behalf of a specific patient for a specific unapproved product. Since March 2021 the TGA reclassified medicinal cannabis products to "SAS-B notifiable," meaning the prescribing doctor notifies the TGA rather than seeking prior approval, a significant reduction in administrative burden. The approval rate for these notifications has consistently sat above 95% based on published TGA data.

The second pathway is the Authorised Prescriber (AP) scheme. Here a doctor applies to the TGA (usually with endorsement from a specialist college or a Human Research Ethics Committee) to prescribe a class of unapproved products to a class of patients without submitting individual applications. Once approved, an AP can prescribe within their authorisation without notifying the TGA for each patient. For high-volume prescribers this is the operationally preferred route.

The practical difference is one of scale. SAS is built around the individual patient and the individual product; AP is built around a defined class of products and patients, which is why it suits prescribers who see many similar cases.

Neither pathway constitutes TGA endorsement that a product is proven effective. The TGA's approval of an SAS or AP application is an access decision, not an efficacy ruling. That distinction matters and is frequently blurred in public discussion, including in marketing, which is one reason the advertising rules for therapeutic goods are so tightly drawn.

Good Manufacturing Practice and product quality

Before a product can even be considered under an access pathway, it must be manufactured to Good Manufacturing Practice (GMP) standards. For medicinal cannabis, the TGA requires either TGA GMP certification of the Australian manufacturer, or evidence of acceptable overseas GMP compliance for imported products. GMP governs everything from testing methodology to batch consistency to labelling accuracy; it's how regulators gain reasonable confidence that what's on the label matches what's in the product.

Put plainly, GMP is about process rather than outcome. It does not say a product works. It says the product was made, tested and documented under controlled conditions, so that one batch can be compared with the next. The licensing side is explained in TGA Good Manufacturing Practice Licensing.

This is worth understanding if you're reading research on full-spectrum or broad-spectrum extracts, where the ratio of CBD, THC, minor cannabinoids and terpenes is precisely the variable under study. GMP-compliant manufacturing is what makes reproducible science possible in this space. If the composition of a test product drifts between batches, any finding about it is hard to interpret. The terminology itself is unpacked in Full-Spectrum vs Isolate: What the Terms Actually Mean.

The 2021 CBD rescheduling: what actually changed

In February 2021 the TGA moved certain low-dose CBD preparations to Schedule 3, pharmacist-only, no prescription required. On paper this was a landmark change. In practice, as of mid-2024, no product had successfully cleared the full ARTG registration pathway required to sit on pharmacy shelves under that schedule. The formulation requirements (maximum 150 mg/day CBD, no other cannabinoids above trace levels, specific labelling) created a narrower gate than the headline suggested.

The gap between regulatory possibility and market reality is worth keeping in mind whenever a headline announces a change. A rescheduling decision removes a legal barrier; it does not create a registered product. Someone still has to prepare the evidence, pay for the registration process and meet the conditions, and that sponsor-side effort is where the delay sits. The rescheduling opened a legal lane; the lane is currently mostly empty. I reckon that will change as more sponsors invest in the registration process, but the timeline remains uncertain. For the wider context, see CBD and Down-Scheduling in Australia.

State permits, research gaps and an honest assessment

Federal scheduling sets the floor. States and territories then apply their own controlled-drugs legislation on top. In the ACT, Schedule 8 cannabis products require both the SAS/AP pathway federally and a permit under the ACT's Medicines, Poisons and Therapeutic Goods Act 2008 before a pharmacist can dispense. Other jurisdictions have their own variations; Queensland, for example, has had a separate permit system through Queensland Health that has progressively been streamlined for cannabis. Jurisdiction-specific detail is in the Australian Capital Territory regulatory overview, and the Medicinal Cannabis Access in Australia FAQ covers common questions.

The practical implication: a prescribing doctor needs to understand both layers, not just one. A TGA notification approval alone does not authorise dispensing in most states. This is the single most common compliance gap discussed in policy circles.

Understanding the regulatory pathway is separate from understanding the pharmacology. If you want to go deeper on the biological mechanisms, the endocannabinoid system is a reasonable starting point; the framework of receptors and endogenous ligands that cannabis-derived compounds interact with. The pharmacokinetics of cannabis preparations also vary significantly by formulation and route of administration, which has real implications for how clinical studies design dosing protocols. The basics of that variation are in Routes of Administration Compared.

One observation I'd put forward as opinion: the regulatory architecture in Australia is genuinely more coherent than it gets credit for, but it assumes a level of administrative literacy from prescribers that the system doesn't do much to build.

The honest assessment is that the TGA framework for medicinal cannabis is functional, moderately well-designed for a novel category, and still maturing. The SAS-B notification system dramatically reduced friction compared to the pre-2021 prior-approval model. The AP scheme creates a workable high-volume route. The GMP requirements provide a real quality floor. But the state-level permit layer adds friction that federal reform alone cannot resolve, and the Schedule 3 CBD pathway remains more theoretical than practical for now.

None of that is a reason to avoid learning how the system works. If anything, the more widely this framework is understood, by patients, practitioners, researchers and journalists, the better the policy conversations around it tend to be. The agency's own site at tga.gov.au remains the place to confirm current requirements.

Sources

• Regulatory framework for medicinal cannabis; TGA, Australian Government
• Australian Register of Therapeutic Goods (ARTG), TGA, Australian Government
• Medicinal cannabis, Australian Government Department of Health and Aged Care
• Special Access Scheme guidance; TGA, Australian Government

Marcus Hale, Regulatory researcher, TGA & access law